Successful radiotherapy of de novo hypopharyngeal cancer in a Fanconi anemia patient with previous esophageal cancer

Mohammad Babaei1,2 | Kamran Roudini3 | Mohammad Shirkhoda4 | Maryam Ganjalikhani5 | Kasra Kolahdouzan1,2

1Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
2Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3Department of Internal Medicine, Hematology and Medical Oncology Ward, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of medical Sciences, Tehran, Iran
4Department of Oncosurgery, Cancer Institute, Tehran University of Medical sciences, Tehran, Iran
5Department of Sports Medicine, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence
Kasra Kolahdouzan, Cancer Institute, Imam-Khomeini Hospital Complex, Keshavarz Blvd., Tehran, Iran.
Email: kakol_72@yahoo.com

Abstract
Definitive radiotherapy was effectively used for treatment of de novo hypopharyngeal SCC in a previous esophageal cancer patient with a history of Fanconi anemia, resulting in a complete clinical response.

Keywords
esophageal SCC, Fanconi anemia, hypopharyngeal SCC, radiotherapy

1 | INTRODUCTION

Fanconi anemia (FA) is a genetic disorder characterized by a range of phenotypic presentations and susceptibility to malignancies. We report an FA patient with previously treated esophageal cancer, vulvar, and cervical intraepithelial premalignant lesions, who was diagnosed with hypopharyngeal squamous cell carcinoma and was treated successfully with definitive radiotherapy.

Fanconi anemia is an autosomal recessive genetic disorder caused by mutations in any of the 22 FA pathway genes currently identified.1 Initially described by Guido Fanconi in 1927,2 this disorder is characterized by a wide range of phenotypic presentations in musculoskeletal, skin, endocrine, genitourinary, and other body systems, as well as hematologic manifestations and a very high predisposition to cancer.3

According to the International Fanconi Anemia Registry (IFAR), the cumulative incidence of bone marrow failure in FA patients by age 40 is about 90%, usually manifested by thrombocytopenia, anemia, and neutropenia.4

2 | CASE PRESENTATION

A 39-year-old woman, known case of FA and previous esophageal cancer, was referred to our clinic due to a recent new onset dysphagia. She did not manifest any major detectable congenital malformations related to FA except for a short stature. The FA diagnosis was confirmed previously by diepoxybutane DNA cross-linking study. The patient had a sophisticated past medical and surgical history since 7 years ago. When she was 32, after experiencing a long period of
dysphagia and odynophagia for at least 6 months that did not improve with medical treatment, she underwent a diagnostic upper GI endoscopy. Suspicious scattered white plaques were discovered along the middle esophagus, 25 cm far from the incisor teeth. The endoscopic view resembled leukoplakia or eosinophilic esophagitis and with a less probability, recovering herpetic esophagitis. However, the biopsy result indicated invasive well-differentiated squamous cell carcinoma. She underwent total esophagectomy with colon interposition. The surgical pathology report indicated a 2 cm long, circumferential lesion of large cell keratinizing type squamous cell carcinoma with focal submucosal invasion without any metastatic involvement of lymph nodes. All surgical margins were free, and the tumor did not show any features of angiolympathic or perineural invasion. The morbidity of this surgery had been very devastating for the patient due to the massive hematochezia that she experienced a few days after surgery because of anastomosis ulceration and leak. She was kept in the intensive care unit for 3 weeks in order to control the surgery consequences before being discharged. She also had to receive multiple transfusions of platelet units as well as packed red blood cell units, due to her Fanconi-associated thrombocytopenia at that time.

Four years after esophagectomy, she noted multiple unusual skin lesions in her labia majora. She underwent multiple biopsies of the lesions which showed vulvar intraepithelial lesions grade 1-3 (VIN-1-3). Immunohistochemistry results showed positivity for P-16 and human papilloma virus (HPV). Subsequently, she underwent surgery (simple excision) to remove the lesions; however, due to the recurrence of her vulvar lesions, the surgery was repeated three more times. Due to abnormal vaginal spotting, she also had pap smears which showed high-grade squamous intraepithelial lesion, therefore, she underwent colposcopy. Biopsies through colposcopy also indicated cervical intraepithelial neoplasia I (CIN-1) with koilocytosis. She underwent follow-up clinical and colposcopic examinations and cervicovaginal smear testing which showed no further lesions.

After 7 years since her first major surgery (esophagectomy) when she was 39 years old, she experienced dysphagia, odynophagia, and hemoptysis. She declined any past or present cigarette smoking or alcohol consumption. Due to her symptoms, she underwent upper re-endoscopy. It showed a vegetative ulcerative mass in hypopharynx with right pyriformis involvement (Figure 1). Cervical esophagus, esophago-colonic anastomosis, and the rest of the interposed colonic mucosa were normal. Biopsy results indicated well-differentiated squamous cell carcinoma of the hypopharynx. On magnetic resonance imaging (MRI), there was a 20 × 16 mm mass lesion in right pyriformis sinus with suspicious involvement of right aryepiglottic fold which extended inferiorly down to the cricoid level. There was no infiltration of perivertebral fascia or penetration of hypopharyngeal wall (T2N0M0). The patient was discussed in a multi-disciplinary treatment planning session in the presence of radiation oncologists, medical oncologists, pathologists, radiologists, and onco-surgeons. She was offered either surgery including laryngopharyngectomy or definitive radiation therapy. Because of the previous extensive surgery and significant bleeding risk due to her Fanconi anemia-associated thrombocytopenia, and her reluctance for another major surgery, radiation therapy was chosen for her. She was treated with 3D-conformal external beam radiation therapy delivered by 6 MV photons for a total dose of 70 Gy in 35 fractions over 6 weeks. The treatment planning was delivered through two lateral fields with cord sparing after 46 Gy, and delivering 60 Gy to the planning treatment volume consisting of the associated high-risk lymph node levels as well as the primary tumor, and a final boost until 70 Gy to the primary tumor site. She experienced grade 2 mucositis and nausea/vomiting during and for 3 weeks after treatment which resolved afterward.

Before radiotherapy, her WBC counts were around 3000 per microliter (65% neutrophil), hemoglobin was about 9 g/dL (MCV of 97 fL), and platelet levels were below 70 thousand per microliter; therefore, the following medication was prescribed for her: Capsule Danazole 200 mg PO daily, Amp Romiplostim 250 µg SC weekly, Amp Filgrastim 300 µg SC weekly, and Amp Erythropoietin 10 000 IU SC weekly. She received her radiotherapy treatment without delay and with stable WBC, hemoglobin, and platelet counts.

She has been undergoing close follow-up every 3 months after radiotherapy with upper endoscopy, and 1 year after

![FIGURE 1](image-url) Upper endoscopy images showing a vegetative mass in the right pyriform sinus of hypopharynx
treatment, she remains symptom-free without evidence of recurrence or relapse on upper gastrointestinal tract according to the endoscopy and MRI results (Figures 2 and 3).

### DISCUSSION

According to the 20-year results of 754 FA patients from IFAR registry, apart from acute myeloid leukemia, and myelodysplastic syndrome, SCCs of the head and neck, vulvocervical SCCs, and liver tumors are the most common solid tumors in Fanconi anemia patients.5,6 Cumulative incidence of solid tumors in FA patients has been diversely reported to be about 30%-76% by age 45 in the two largest published cohorts.5,6

As FA patients are very susceptible to DNA cross-linking, alkylating chemotherapy agents are contraindicated in them. However, despite remaining concerns about increased risk of secondary malignancies, radiotherapy is inevitably used in relevant clinical situations. Our patient had previously undergone radical esophagectomy with colon interposition, and due to a persistent thrombocytopenia, a second extensive surgery with increased risk of bleeding was not an appropriate option for her.

![FIGURE 2](image1) Upper endoscopy images demonstrating disappearance of the initial mass. Note the mild radiation related edema and erythema.

![FIGURE 3](image2) Timeline showing different procedures done for the patient regarding her malignancies.

There are only a few published cases in the literature that were treated successfully with radiotherapy as a part of their treatment or definitively.7-11

Some studies indicate a severely excessive clinical radiosensitivity mandating radiotherapy cessation in patients with AT (ataxia-telangiectasia) or FA, not correlated with cellular radiosensitivity in the cell line cultures of these patients.12,13

There are very few published cases in the literature with more than one solid malignant tumor associated with Fanconi anemia.5,7,14-17 The patient presented in this article, experienced two malignancies (esophageal and hypopharyngeal SCC), and two loci for recurrent premalignant lesions (vulvar and cervical intraepithelial neoplasia). Fifty-four percent of FA patients with cervical, vulvar, and anal SCCs had a history of HPV-associated condylomas in IFAR;5 however, the association of HPV with head and neck SCCs in FA patients is less well established.18-20 As previously stated, our patient was tested positive for HPV in a biopsy of her vulvar lesions. Whether the genetic mutations in the FA pathway genes make these patients more susceptible to HPV infection is not clearly understood yet; however, these patients are asked to get vaccinated against HPV virus.

Although our patient is currently disease-free 1 year after multiple treatment modalities for her primary cancers and
premalignant lesions, we will have to observe her life-long for any signs of recurrence or new malignant disease, especially that we are concerned about possibility of secondary malignancies following receipt of high dose of radiation.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS
MB, KR and MS: were the physicians in charge of patient treatment, and contributed in data gathering, drafting and scientific revision of the manuscript. MG and KK: contributed in writing, editing, and final revision of the manuscript.

ETHICS APPROVAL
The presented manuscript is concordant with ethical guidelines and all information was included after patient’s written informed consent while maintaining anonymity.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author, K.K, upon request.

ORCID
Kasra Kolahdouzan ORCID 0000-0003-1522-5619

REFERENCES
1. Nepal M, Che R, Zhang J, Ma C, Fei P. Fanconi anemia signaling and cancer. Trends Cancer. 2017;3(12):840-856.
2. Fanconi G. Familiare infantile perniziosartige anamie (pernizioses Blutbild und Konstitution). Jahrbuch Kinderheilk. 1927;117:257-280.
3. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668(1–2):4-10.
4. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi anemia registry: relation of clinical symptoms to diepoxyn-butane sensitivity. Blood. 1989;73(2):391-396.
5. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi anemia registry (IFAR). Blood. 2003;101(4):1249-1256.
6. Alter BP. Cancer in Fanconi anemia, 1927–2001. Cancer. 2003;97(2):425-440.
7. Bremer M, Schindler D, Gross M, Dork T, Morlot S, Karstens JH. Fanconi’s anemia and clinical radiosensitivity report on two adult patients with locally advanced solid tumors treated by radiotherapy. Strahlenther Onkol. 2003;179(11):748-753.
8. Wong WM, Parvathaneni U, Jewell PD, et al. Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: a case report and review of the literature. Head Neck. 2013;35(10):E292-E298.
9. Budrukkar A, Shahid T, Murthy V, et al. Squamous cell carcinoma of base of tongue in a patient with Fanconi’s anemia treated with radiation therapy: case report and review of literature. Head Neck. 2010;32(10):1422-1427.
10. Lewis LM, Tang AL, Wise-Draper TM, Myers KC, Greenberger JS, Takiar V. Successful use of a therapeutic trial of graduated volume and dose escalation for postoperative neck and head radiotherapy in a Fanconi anemia patient. Head Neck. 2020;42(10):1-7.
11. Harper JL, Jenrette JM, Goddu SM, Lal A, Smith T. Vulvar cancer in a patient with Fanconi’s anemia, treated with 3D conformal radiotherapy. Am J Hematol. 2004;76(2):148-151.
12. Marcou Y, D’Andrea A, Jeggo PA, Plowman PN. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. Radiat Oncol. 2001;60(1):75-79.
13. Rogers PB, Plowman PN, Harris SJ, Arlett CF. Four radiation hypersensitivity cases and their implications for clinical radiotherapy. Radiat Oncol. 2000;57(2):143-154.
14. Sari N, Akyuz C, Aktas D, et al. Wilms tumor, AML and medulloblastoma in a child with cancer prone syndrome of total premature chromatid separation and Fanconi anemia. Pediatr Blood Cancer. 2009;53(2):208-210.
15. Dosik H, Verma R, Wilson C, Miotti A, editors. Fanconi Anemia and a Familial Stable Chromosome Abnormality in a Family with Multiple Malignancies. Blood; Philadelphia; PA: WB Saunders co independence square west curtis center, 1977.
16. Nara N, Miyamoto T, Kurisu A, et al. Two siblings with Fanconi’s anemia developing squamous cell carcinomas. Rinsho Ketsueki. 1980;21:1944-1950.
17. Kennedy AW, Hart WR. Multiple squamous-cell carcinomas in Fanconi’s anemia. Cancer. 1982;50(4):811-814.
18. Toptan T, Brusadelli MG, Turpin B, et al. Limited detection of human polyomaviruses in Fanconi anemia related squamous cell carcinoma. PLoS One. 2018;13(12):e0209235.
19. Van Zeeburg HJ, Snijders PJ, Wu T, et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst. 2008;100(22):1649-1653.
20. Winer RL, Huang CE, Cherne S, et al. Detection of human papillomavirus in the oral cavities of persons with Fanconi anemia. Oral Dis. 2015;21(3):349-354.

How to cite this article: Babaei M, Roudini K, Shirkhoda M, Ganjalikhani M, Kolahdouzan K. Successful radiotherapy of de novo hypopharyngeal cancer in a Fanconi anemia patient with previous esophageal cancer. Clin Case Rep. 2021;9:e04159. https://doi.org/10.1002/ccr3.4159